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he  volume  of  information  that  is  presented   
to practitioners is increasing at an incredible pace. 
Addressing  this,  we  previously  described  some 
practical surveillance strategies for providers to flag im-
portant evidence and keep up to date on the current state 
of medical knowledge.1 Using these strategies, we iden-
tified five notable articles for general internal medicine 
published in late 2009 and in 2010. Here, we present a 
focused summary of these articles, supported by clinical 
vignettes to highlight the importance of their findings. 
We then reflect on the rich and ongoing advances made 
to the global body of medical knowledge by investigators 
and collaborators worldwide.
Target rate control in patients with atrial 
fibrillation
Clinical  vignette.  A  76-year-old  woman  with  chronic 
atrial  fibrillation  receives  long-term  rate  control  with 
metoprolol at a dose of 50 mg b.i.d. She has a normal 
exercise tolerance. On examination, she is asymptomatic 
with a resting heart rate of 90–110 beats/minute and 
blood pressure (BP) of 110/70 mmHg. Should her rate 
control therapy be modified?
Summary of findings. The RACE II trial (Rate Control 
Efficacy in Permanent Atrial Fibrillation: a Comparison 
between  Lenient  versus  Strict  Rate  Control  II)  was  a 
multicentre, prospective, randomized, open-label, non-
inferiority  trial  designed  to  compare  two  rate  control 
strategies  in  patients  with  chronic  atrial  fibrillation.2 
Six hundred and fourteen (614) patients were randomly 
assigned to receive either a lenient rate control strategy 
(target resting heart rate < 110 beats/minute), or a strict 
rate control strategy (target resting heart rate < 80 beats/
minute and < 110 beats/minute during moderate exer-
cise). Targets were achieved in 304 of 311 patients (97.7%) 
in the lenient rate control group, as compared with 203 
of 303 patients (67.0%) in the strict rate control group. 
Lenient  rate  control  did  not  differ  significantly  from 
strict rate control for the primary outcome, a composite 
of cardiovascular mortality, hospital admission for heart 
failure, stroke, systemic embolism, major bleeding, and 
arrhythmic events at 3 years (hazard ratio [HR] 0.84; 
90% confidence interval [CI] 0.58–1.21; p = 0.001 for 
non-inferiority). Individually, the outcomes of all-cause 
mortality, cardiovascular death, heart failure, bleeding, 
hospital admissions and adverse drug events were not 
statistically different between groups. However, a sig-
nificant difference in stroke rates was observed in favour 
of lenient rate control (HR 0.35; 90% CI 0.13–0.92). The 
study was funded by the Netherlands Heart Foundation, 
AstraZeneca, Biotronik, Boehringer Ingelheim, Boston 
Scientific, Medtronic, Roche and Sanofi Aventis France. 
The  authors  assert  that  none  of  the  sponsors  was  in-
volved in the study design, data collection, data analysis 
or manuscript preparation.
Implication and perspectives. The results of this trial 
are  both  surprising  and  potentially  transformative  to 
care recommendations for atrial fibrillation. Strict rate 
control has been widely recommended by guidelines for 
the management of chronic atrial fibrillation.3  However, 
with the first randomized controlled trial (RCT) on this 
topic, the RACE II investigators concluded that a lenient 
Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings 
AM, et al.  Lenient versus strict rate control in patients with atrial 
fibrillation.  N Engl J Med 2010;362(15):1363–1373. Available from: 
www.nejm.org/doi/full/10.1056/NEJMoa1001337.
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rate  control  strategy  was  non-inferior  to  a  strict  rate 
control  strategy  in  terms  of  important  major  clinical 
outcomes. The interpretability of the primary outcome 
of interest is challenging because it was a complex com-
posite of diverse events, many of which do not directly 
relate to heart rate (e.g., major bleeding). Further, symp-
tom assessment and quality-of-life measures were not 
included. Nonetheless, individual components relating 
to rate control, such as hospital admissions for heart 
failure,  arrhythmic  events  and  cardiovascular  death 
were similar between the two treatment groups. The re-
sults of this well-conducted study should guide clinical 
management. Lenient rate control appears to be an ad-
visable treatment strategy for the majority of asymptom-
atic patients with chronic atrial fibrillation. In contrast, 
strict rate control may be inconvenient and undesirable 
for some patients and providers because of the frequent 
outpatient examinations required to achieve targets, the 
potential increased risk of medication-related side ef-
fects, and the possible increased risk of stroke. Finally, 
although the results of this study pertain to the manage-
ment of chronic atrial fibrillation, they might not neces-
sarily apply to patients with new-onset atrial fibrillation.
Resolution of clinical vignette. In the absence of symp-
toms, the findings of this trial suggest that no changes 
should be made to this patient’s medication list, whereas 
the prior approach would have been to increase her dose 
of metoprolol. Therefore, she continues on her current 
dose of metoprolol to maintain a resting heart rate of 
< 110 beats/minute.
Preventing surgical-site infections in carriers  
of S. aureus
Clinical vignette. A recent local hospital-wide audit re-
veals that 18% of admitted patients are nasal carriers for 
methicillin-sensitive  Staphylococcus  aureus,  and  the 
prevalence of S. aureus–associated nosocomial infec-
tions is reported to be as high as 10%. Hospital infection 
control practitioners wonder whether anything can be 
done to address these challenges.
Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-
Grauls CM, Roosendaal R, et al.  Preventing surgical-site infections in 
nasal carriers of Staphylococcus aureus.  N Engl J Med 2010;362(1):9–
17.  Available from: www.nejm.org/doi/full/10.1056/NEJMoa0808939. 
Summary of findings. Bode and colleagues conducted a 
randomized, placebo-controlled trial across 5 hospitals 
in the Netherlands, evaluating the benefit of targeted 
decolonization  in  preventing  S.  aureus–associated 
nosocomial  infections.4  Nine  hundred  and  seventeen 
(917)  participants  were  identified  after  6771  patients 
were screened for the presence of S. aureus by real-time 
polymerase chain reaction assay. They were then ran-
domly  assigned  to  receive  active  treatment  (with  2% 
mupirocin nasal ointment applied twice daily in com-
bination  with  chlorhexidine  soap  for  daily  total-body 
wash), or double placebo for a total treatment course of 
5 days with repeated treatments, if necessary, for longer 
hospital stays at 3  and 6 weeks. Participants were fol-
lowed for 6 weeks after discharge. The cumulative inci-
dence of hospital-associated S. aureus infections was 
significantly  lower  in  the  mupirocin-chlorhexidine 
group than in the placebo group (absolute event rates 
3.4% v. 7.7%; relative risk [RR] 0.42; 95% CI 0.23–0.75; 
number needed to treat [NNT] 23) with no significant 
difference  between  surgical  and  nonsurgical  patients 
after adjustment. Treatment with mupirocin-chlorhexi-
dine  versus  placebo  was  associated  with  fewer  infec-
tions  from  endogenous  sources,  as  determined  by 
molecular typing (RR 0.39; 95% CI 0.20–0.77), fewer 
deep  surgical  site  infections  (RR  0.21;  95%  CI  0.07–
0.62), and shorter hospital stays (mean 12.2 days v. 14.0 
days; p = 0.04). The study was inadequately powered to 
detect a significant difference in mortality. This study 
was  supported  by  grants  from  ZonMw,  Mölnlycke 
Health Care, GlaxoSmithKline, Roche, bioMérieux and 
3M. The authors assert that the sponsors did not influ-
ence the study design, data collection, analysis or writ-
ing of the manuscript.
Implication  and  perspectives.  Bode  and  colleagues  in-
tro    duce a novel hospital-care paradigm with tremendous 
potential for reducing rates of S. aureus–associated noso-
comial infections. The strength of association and mag-
nitude  of  benefit  reported  with  this  intervention  are 
impressive.  However,  several  issues  remain  unresolved: 
can the results of this study be generalized to populations 
with a greater prevalence of methicillin-resistant S. aureus; 
will nonselective decolonization be effective against non–S. 
aureus pathogens; and, is targeted decolonization cost ef-
fective? This study is likely to inspire further patient-safety 
research to inform policy-makers and providers.
Resolution of clinical vignette. A hospital-wide protocol 
for targeted decolonization of nasal carriers of S. aureus 
is considered for the hospital in question, although site 
administrators agree that an analysis of the local cost 
implications and potential savings is needed.
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with type 2 diabetes
Clinical vignette. A 45-year-old man with type 2 dia-
betes and hypertension is seen in follow-up. He has no 
evidence of renal disease. His blood pressure medica-
tions are ramipril 2.5 mg b.i.d. and amlodipine 5 mg q.d.   
He denies any side-effects from treatment.  On examina-
tion, he has a BP of 128/74 with no postural change. His 
physician ponders whether his BP is on target. 
 
ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC 
Jr, Grimm RH Jr, et al.  Effects of intensive blood-pressure control in 
type 2 diabetes mellitus.  N Engl J Med 2010;362(17):1575–1585. Avail-
able from: www.nejm.org/doi/full/10.1056/NEJMoa1001286.
Summary of findings. The ACCORD BP trial (Action 
to Control Cardiovascular Risk in Diabetes blood pres-
sure)  was  an  open-label,  randomized  controlled  trial 
conducted at 77 centres in the United States and Can-
ada, involving 4733 patients with type 2 diabetes and 
hypertension.5 Participants were randomly assigned to 
receive intensive antihypertensive therapy with a tar-
get systolic BP < 120 mmHg (2362 patients) or standard 
therapy with a target systolic BP < 140 mmHg (2371 pa-
tients). Mean blood pressures achieved at 1 year were 
119 mmHg and 134 mmHg in the intensive and stan-
dard control groups, respectively, and these levels were 
maintained throughout the trial. Intensive therapy and 
standard  therapy  were  similar  for  the  primary  out-
come, a composite of nonfatal myocardial infarction, 
nonfatal  stroke,  and  cardiovascular  death  (absolute 
event rates 1.87%/year v. 2.09%/year; HR 0.88; 95% CI 
0.73–1.06; p = 0.20) with a mean follow-up of 4.7 years. 
No statistical difference was observed in the individual 
rates of nonfatal myocardial infarction, major coronary 
disease, heart failure or death. However, a significant 
reduction in stroke was reported with intensive ther-
apy v. standard therapy (HR 0.59; 95% CI 0.39–0.89; 
p = 0.01; NNT 95). Patients receiving intensive control 
were more likely to have serious adverse drug events 
(p < 0.001), hypokalemia (p < 0.01) and elevated cre-
atinine levels (p < 0.001), but less macroalbuminuria 
(p = 0.009). The trial was sponsored by the National 
Heart, Lung, and Blood Institute (NHLBI). Drugs were 
donated  by  Abbott  Laboratories,  AstraZeneca  Phar-
maceuticals,  GlaxoSmithKline  Pharmaceuticals,  King 
Pharmaceuticals,  Sanofi-Aventis  U.S.  and  Novartis 
Pharmaceuticals.  Sphygmomanometers  were  donated 
by  Omron  Healthcare.  The  authors  assert  that  these 
companies had no role in the design of the study, the 
accrual or analysis of the data or the preparation of the 
manuscript.
Implication and perspectives. High-quality evidence to 
support existing recommendations to target systolic BP 
< 130 mmHg for patients with diabetes is lacking.6,7 Al-
though ACCORD BP does not conclusively determine the 
optimal systolic BP target for patients with diabetes, its 
results are nonetheless informative. This study was the 
first rigorously conducted trial to compare two different 
BP treatment strategies in patients with diabetes at high 
cardiovascular risk, and found that intensive antihyper-
tensive therapy did not significantly reduce a composite 
of major adverse cardiovascular events more than stan-
dard therapy.5 However, these conclusions must be in-
terpreted with caution. First, the trial was designed to 
detect a 20% reduction of the rate of the primary com-
posite outcome in the intensive-therapy group compared 
with the standard-therapy group, assuming an event rate 
of 4% per year among those receiving standard therapy.   
In fact, the observed event rate was almost 50% lower 
than expected among those receiving standard therapy.   
Consequently, the reduced power (resulting in relatively 
wide confidence intervals) does not exclude a 12% rela-
tive risk reduction for the primary outcome. Moreover, 
follow-up beyond 5 years may be needed to observe a sig-
nificant cardioprotective benefit, as seen in other anti-
hypertensive trials. Second, the statistically significant 
41% relative risk reduction reported for strokes in those 
receiving  intensive  therapy  is  neither  clinically  insig-
nificant nor inconsequential. Therefore, it is important 
to emphasize that, although this trial was inadequately 
powered to detect a significant reduction in composite 
cardiovascular events, intensive BP control lowers stroke 
risk at the expense of more serious adverse drug events.     
Accordingly,  when  applying  this  evidence  to  the  bed-
side, providers need to weigh the benefits and risks of 
intensive therapy according to individualized risks and 
patient preferences.
Resolution  of  clinical  vignette.  Although  this  trial’s 
results leave some questions unanswered, the findings 
still point to some potential benefit for tight blood pres-
sure control, particularly in patients such as this one, for 
whom drug dosages are modest and there are no medica-
tion side-effects relating to current therapy. Therefore, 
this  patient’s  dosage  of  ramipril  is  increased  to  5 mg 
b.i.d.  in  an  effort  to  lower  his  blood  pressure  further 
and reduce future risk of ischemic stroke. The patient is 
agreeable to this plan, as he is currently free from medi-
cation-related side-effects.
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vascular surgery
Clinical vignette. A 52-year-old man with severe, symp-
tomatic peripheral arterial disease is seen in the pre-
operative assessment clinic in preparation for a femoral 
popliteal  bypass  scheduled  in 6 weeks. He  takes  low-
dose  acetylsalicylic  acid  and  metoprolol.  He  inquires 
about other strategies to lower his perioperative cardio-
vascular risk. 
Schouten O, Boersma E, Hoeks SE, Benner R, van Urk H, van Sambeek 
MR, et al.  Fluvastatin and perioperative events in patients undergo- Fluvastatin and perioperative events in patients undergo-
ing vascular surgery.  N Engl J Med 2009;361(10):980–989.  Available 
from: www.nejm.org/doi/full/10.1056/NEJMoa0808207.
Summary of findings. This Dutch study was a random-
ized placebo-controlled trial of 497 patients scheduled 
for vascular surgery, designed to evaluate the benefit of 
perioperative  fluvastatin  in  reducing  the  incidence  of 
cardiac events.8 Patients were randomly assigned to re-
ceive  either  80  mg  of  extended-release  fluvastatin,  or 
placebo (median 37 days before surgery); those not al-
ready receiving beta-blocker therapy were also started 
on bisoprolol 2.5 mg once daily at the time of randomiza-
tion. Treatment was continued for at least 30 days post-
operatively. Patients receiving fluvastatin v. placebo had 
a decreased risk of myocardial ischemia, as defined by 
transient ischemic changes on electrocardiogram, eleva-
tion of troponin T, or both (absolute event rates within 
30 days of surgery 10.8% v. 19.0%; HR 0.55; p = 0.01; 
NNT 12), and a decreased risk for the composite outcome 
of cardiovascular death and myocardial infarction (abso-
lute event rates within 30 days of surgery, 4.8% v. 10.1%, 
HR 0.47; p = 0.03; NNT 19). There were no reports of 
myopathy or rhabdomyolysis in either group. This study 
was supported by unrestricted grants from Novartis, the 
Netherlands Organization for Health Research and De-
velopment, the Erasmus Medical Center, Stichting Lijfen 
Leven and the Netherlands Heart Foundation. The auth-
ors assert that none of the funding sources had a role in 
the design or conduct of the trial, analysis of data or re-
porting of the results.
Implication  and  perspectives.  The  findings  of  this 
study strengthen existing recommendations for perio-
perative statin therapy for patients undergoing vascular 
surgery who are at high risk for cardiac complications.9 
This study offers RCT evidence for the benefit of statin 
therapy  over  and  above  concomitant  beta-blockade  in 
the setting of vascular surgery. Although a significant 
proportion of patients with peripheral arterial disease 
will already be on statins given the demonstrated bene-
fits from long-term statin therapy in such patients,10 this 
trial calls attention to the relatively short-term, but im-
portant, benefits of perioperative treatment. Therefore, 
scheduled preoperative encounters with patients prior to 
planned vascular surgeries may provide meaningful op-
portunities for clinicians to improve perioperative and 
long-term  outcomes  with  a  simple  intervention  ,  espe-
cially for those not already on existing statin treatment. 
Although these findings can likely be generalized to all 
statins, further research is required to define the optimal 
time to initiate statin therapy in the preoperative setting.
Resolution of clinical vignette. In the absence of any 
contraindications to statin therapy, this man is started 
on fluvastatin 80 mg once daily preoperatively in addi-
tion to his current medications and is continued on long-
term statin therapy.
The use of A1C for the screening and diagnosis 
of type 2 diabetes
Clinical vignette. A 68-year-old man is referred for in-
terpretation of laboratory blood tests performed by his 
family physician. He has a single fasting plasma glucose 
measurement of 5.2 mmol/L and a hemoglobin A1C of 
6.4%.
Lu ZX, Walker KZ, O’Dea K, Sikaris KA, Shaw JE.  A1C for screening and 
diagnosis of type 2 diabetes in routine clinical practice.  Diabetes Care 
2010;33(4):817–819. Available from: http://care.diabetesjournals.org/
content/33/4/817.full. 
Summary of findings. Lu and colleagues evaluated the 
use of A1C as a screening and diagnostic tool for type 2 
diabetes in a clinic-based cohort of 2494 patients from 
Melbourne, Australia, and a population-based cohort of 
6015 patients derived from the national AusDiab study.11 
A1C levels were standardized to Diabetes Control and 
Complications  Trial  (DCCT)–aligned  values.  All  par-
ticipants  concurrently  received  an  oral  glucose  toler-
ance test (OGTT) as the gold standard diagnostic test 
and were classified according to the American Diabetes 
Association (ADA) criteria for the presence or absence 
of  diabetes.12  Among  patients  without  diabetes  in  the 
clinic-based cohort, A1C levels of 5.6% and 6.9% corres-
ponded to the 2.5th and 97.5th percentiles, respectively.   
Thus, an A1C ≤ 5.5% was identified as a strong thresh-
old for “ruling out” diabetes, and ≥ 7.0% for “ruling in” 
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cohorts, these two cutoffs were associated with moder-
ate to high sensitivities (83.5% and 97.8%), high specifi-
cities (98.2% and 100%), high negative predictive values 
(NPV) (95.8% and 99.0%), and high positive predictive 
values (PPV) (92.9% and 100%). In contrast, when vari-
ous A1C cutoffs were tested, a value of 6.2% was found 
to be the single most discriminating cut-point, and as-
sociated with a sensitivity of 82.2%, specificity of 78.8%, 
NPV of 89.3%, PPV of 67.2%, positive likelihood ratio 
(LR+) of 3.9, and negative likelihood ratio (LR−) of 0.2. 
Although no direct funding was reported for this study, 
funding  sources  for  the  original  AusDiab  study  were 
clearly disclosed in the original publication.13
Implication and perspectives. For decades, the diagno-
sis of diabetes has been based on conventional glucose 
measurements.12  However,  current  evidence  supports 
the use of A1C as an acceptable and convenient alterna-
tive. Here,11 Lu and colleagues uniquely demonstrated 
that the use of two A1C cutoffs offered superior diagnos-
tic characteristics compared to a single cutoff of 6.5% 
as recommended by the International Expert Commit-
tee and the ADA guidelines.12,14 Importantly, this study 
highlights that A1C values > 5.5% are associated with es-
calating risks for impaired fasting glucose, impaired glu-
cose tolerance, and diabetes. These findings are in broad 
agreement with other reports that describe similar gra-
dients of increasing risk for diabetes, microvascular and 
macrovascular  complications,  and  all-cause  mortality 
associated with increasing A1C.15,16 Although it appears 
that A1C cutoffs of ≤ 5.5% and ≥ 7.0% accurately rule out 
and rule in diabetes, respectively, individuals with “im-
paired” A1C levels between 5.5% and 7.0% should also be 
considered to be at risk for dysglycemia and its associ-
ated complications. 
Resolution of clinical vignette. Strictly speaking, this 
patient does not meet the current criteria for the diagno-
sis of diabetes because his A1C is below 6.5%.12  However, 
his A1C level is above the optimal discriminating thresh-
old of 6.2%. Thus, some experts may still consider him 
to have diabetes on that basis. Others, however, would 
point out that, regardless of where he sits relative to the 
proposed thresholds that dichotomize diabetes into two 
discrete groups (yes v. no), the patient has an abnormal 
glucose metabolism and is at a higher risk for developing 
associated microvascular and macrovascular complica-
tions.  Therefore, he is referred for a 75-g oral glucose tol-
erance test and, regardless of its result, receives attentive 
lipid and blood pressure assessments and management.   
He is also provided with appropriate advice for lifestyle 
modification.
Marvelling at advances in medical knowledge
This is truly an exciting era! We are witnessing unpreced-
ented growth in scientific discovery and an impressive 
uptake of new knowledge. Indeed, the medical research 
community is highly productive and vibrant.  
In particular, the introduction of clinical trials and 
evidence-informed  medicine  has  resulted  in  a  vast 
wealth of medical literature. The first randomized clin-
ical  trial  in  1948,  which  compared  streptomycin  with 
placebo in the treatment of pulmonary tuberculosis, left 
a legacy through which subsequent clinical trials were 
conducted,17,18 providing much of the rational evidence 
for current treatment policies. Further, the widespread 
adoption  of  trial  results  into  clinical  practice  has  re-
sulted in an exponential growth in the number of clinical 
trials  being  conducted  worldwide.  Various  trial  regis-
tries have been established to facilitate accessibility, im-
prove research transparency and ultimately strengthen 
the global scientific evidence base (e.g., clinicaltrials.gov, 
isrctn.com and controlled-trials.com). There are now im-
pressively over 100 000 trials registered to ClinicalTri-
als.gov alone.
The  tremendous  productivity  in  the  research  com-
munity is the result of the incredible work of diligent in-
vestigators, inquisitive minds posing practice-changing 
questions (e.g., Is strict rate control optimal for patients 
with permanent atrial fibrillation?     — a truly important 
yet basic question that, intriguingly, has only been posed 
now, well into the 21st century after decades of therapy 
provided  by  practitioners  in  a  void  of  evidence),  and 
the emergence of hybrid funding strategies to support 
intensive investigation (through a combination of gov-
ernment agencies, industry, charitable foundations and 
philanthropic donations). Also importantly, proponents 
of evidence-informed medicine have been instrumental 
in the promotion of information uptake through educa-
tion, the dissemination of literature, and the creation of 
knowledge repositories. With the continual flow of new 
information, we gain greater insights into medicine, re-
fine our practices, and explore new paradigms of care.
Finally, although the five articles that we have high-
lighted here are indisputably important, we would be re-
miss not to emphasize that countless other high-quality 
and important articles were published during the period 
covered by our selection. All users of evidence are greatly 
indebted to the many investigators who have facilitated 
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Open Medicine 2011;5(1):e53the growth of medical knowledge through the publica-
tion of their research. Their work will certainly save lives 
and enhance care, and we should all applaud them for 
their impressive work. 
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of  the manuscript and read and approved the final manuscript for 
publication. 
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